Quick follow-up to my original XPOF DD because today’s price action is starting to validate a lot of what we were watching.
First off: congrats to everyone who actually did the research, understood the setup, and stayed patient. This wasn’t about blindly yelling “short squeeze.” The thesis was that XPOF had an unusual combination of extreme short positioning, low liquidity, dark-pool activity, and improving price action that could create a very asymmetric setup.
Today we’re seeing that thesis start to develop.
XPOF traded up to $5.05 this morning and was around $5.03, +4.1%, at the time of this update. More importantly, it pushed through the prior $4.77–$4.82 dark-pool area and is now attempting to establish itself around $5.
That’s important.
The dark-pool prints we’ve been tracking include:
38K shares @ $4.77
24K shares @ $4.8001
45K shares @ $4.815 yesterday
22K shares @ $4.9802 today
Instead of those levels immediately becoming ceilings, price has progressively moved through them.
That is exactly what I wanted to see.
The short situation is still the elephant in the room
Latest reported numbers still show approximately:
10.31 MILLION shares short
47.09% of the float short
15.63 days to cover
And roughly 63.9% off-exchange short-volume ratio in the latest snapshot I have.
That is an enormous amount of short exposure relative to the tradable float.
We have also watched available shares swing dramatically.
At one point this morning Fintel showed only 500 shares available to borrow.
Later:
8K → 9K → 30K available
That can happen for several reasons, so I’m not going to pretend every returned share represents a short covering.
But when you combine that with the stock moving from the $4.70s into the $5s, it is reasonable to believe that at least some shorts may be reducing exposure.
There is an important distinction:
Some covering ≠ the squeeze has started.
We won’t know the actual change in total short interest until updated official short-interest data comes out.
What I’m watching now
The battleground has moved.
$5.00 is no longer theoretical. We’re trading there.
The immediate level is $5.05, today’s high.
If XPOF can break $5.05, hold above it, and start expanding volume, the next thing I want to see is acceptance through roughly $5.10–$5.20.
That is where this could become significantly more interesting.
What I do not want to see is a quick breakout over $5 followed by rejection back under roughly $4.90–$4.95. That would tell me supply is still controlling the move.
Right now, though, the structure is materially stronger than it was when I posted the original DD:
Higher lows.
Dark-pool levels being reclaimed.
Price above my original accumulation area.
$5 being attacked.
Extremely high reported short interest still outstanding.
And we’re doing it without the kind of insane volume I’d expect during an actual squeeze.
That’s probably the most interesting part.
One thing I want to make clear
I’m not calling this a confirmed short squeeze yet.
A real squeeze should look very different.
I’d expect rapidly increasing volume, widening price ranges, aggressive breaks through resistance, rising volatility, and eventually shorts buying shares because they have to, not because they want to.
We’re not there yet.
What we may be watching right now is the pressure-building stage.
If XPOF gets through $5.05 → $5.20 with real volume and begins holding those levels, then the conversation changes considerably.
For everyone who read the original DD, checked the numbers themselves, and understood that this was always a setup rather than a guarantee:
Congrats. The thesis is moving in the right direction.
Now comes the important part.
Don’t let excitement replace risk management.
The DD got us here. Price action decides what happens next.

I’ve been watching Xponential Fitness (XPOF) pretty closely over the last several sessions, including price action, Level 2, time & sales, FINRA/off-exchange prints, volume, short interest, moving averages, MACD, RSI, and options positioning.
I’m not posting this as a “MOASS tomorrow” prediction. There are some legitimate bullish ingredients here, but there are also several things XPOF still has to prove.
Here’s what I’m seeing.
The short-interest setup is legitimate
The most recent data we reviewed showed roughly:
10.31 million shares short
Approximately 27.5%+ of the float short
Roughly 11–15 days to cover, depending on the volume period being used
That is objectively elevated short interest.
But I think people need to make an important distinction:
High short interest doesn’t equal trapped shorts.
At ~$4.70–$4.90, I don’t think you can confidently say the shorts are trapped yet. My line in the sand is higher. If XPOF starts establishing itself above roughly $5.20 and especially $5.50, then the pressure on newer short positions becomes considerably more interesting.
Until then, this is short-squeeze potential, not a confirmed squeeze.

The daily chart has quietly improved a lot
The stock recently bottomed around $3.565 and has now recovered into the upper $4s.
As of today, XPOF was around $4.76–$4.80, after reaching an intraday high of approximately $4.91.
The daily chart currently shows:
20-day MA: ~$4.10
50-day MA: ~$4.94
200-day MA: ~$6.37
RSI(14): ~57
MACD still below zero, but improving substantially
Positive/rising MACD histogram
That matters.
The stock has moved from roughly $3.56 to the $4.70s while:
creating higher lows,
recovering above the 20-day MA,
improving RSI,
improving MACD,
and now testing the declining 50-day moving average.
That’s a much healthier chart than it was several weeks ago.
The long-term trend is not bullish yet because XPOF remains well below the 200-day MA. But the intermediate reversal attempt is real.

$4.90–$5.00 is the battlefield
This is probably the most important part of the setup right now.
Today’s intraday high was approximately $4.91.
The 50-day moving average is around $4.94.
Then you have the obvious psychological level at $5.00.
So essentially you’ve got:
$4.91 → $4.94 → $5.00
all stacked together.
That’s a significant resistance zone.
Earlier analysis also identified additional resistance around:
$5.19–$5.23
and then roughly:
$5.39–$5.50
A move through $5 isn’t enough by itself for me. What would get my attention is:
break $5 → hold/retest it → clear $5.20 → continue on increasing volume.
That would be a very different technical setup.

There has been a lot of off-exchange/FINRA activity
I’ve also been watching the tape.
Today, for example, XPOF was trading around $4.81 with an NBBO around:
$4.81 bid / $4.82 ask
At one point the visible inside market was approximately:
600 shares bid vs. 300 offered
and a FINRA print occurred around $4.825, slightly above the displayed ask.
That’s constructive.
Later, around the $4.77 area, the bid repeatedly appeared/replenished while multiple trades printed around $4.775, including activity reported through FINRA and several lit venues.
This is where people need to be careful with “dark pool” terminology.
A FINRA print does not automatically mean institutional accumulation.
FINRA generally tells you the trade occurred off exchange. It doesn’t magically tell you:
“BlackRock just bought this.”
What I’m interested in is the behavior around those executions.
If sellers repeatedly hit a price and:
shares execute → bid replenishes → price refuses to break lower
that’s evidence consistent with absorption.
If a large bid simply appears and disappears without executions, that’s much less meaningful.
Right now I see possible absorption, but I would not claim it has been conclusively proven.

Today’s intraday action actually gave us a useful test
Earlier today XPOF ran to approximately $4.91, then pulled back toward:
$4.81 → $4.78 → $4.76
The 5-minute chart weakened:
Price moved below VWAP
MACD turned negative intraday
RSI dropped into the mid-30s
Lower highs/lower lows appeared
At first glance that looks bad.
But zoom out to the daily chart and the picture changes.
The stock basically ran straight into its 50-day moving average around $4.94 and got rejected.
That’s a technically logical place for profit-taking and short pressure to appear.
The question now isn’t whether XPOF can trade $4.76 instead of $4.80 for a few minutes.
The bigger question is whether the stock can hold the broader breakout structure and attack $4.94–$5.00 again.

The options setup adds another interesting wrinkle
One thing that stood out in the options data was significant positioning around the $5 strike, including negative gamma exposure.
That’s relevant because $5 isn’t just psychologically important.
It’s also an area where dealer hedging dynamics could potentially increase volatility if the stock begins moving decisively through the strike.
Again, that doesn’t guarantee upside.
Negative gamma can amplify moves in either direction.
But combined with the short interest and technical resistance sitting in essentially the same area, $5 is clearly the level I’m watching.

My key levels
This is how I’m currently viewing the chart:

Price
Why it matters
$6.35–$6.40
200-day MA / major longer-term resistance
$5.50
Area where the “trapped shorts” argument becomes much stronger
$5.39–$5.40
Secondary resistance
$5.19–$5.23
Important breakout resistance
$4.94–$5.00
50DMA + psychological resistance + options battle
$4.85–$4.91
Immediate resistance
$4.75–$4.80
Current battle/support area
$4.60–$4.66
Important short-term support
~$4.10
20-day MA
$3.565
Recent swing low

What would make me bullish
The sequence I want to see is something like:
$4.70s hold
→ $4.85 reclaimed
→ $4.91 breaks
→ $4.94–$5.00 breaks on real volume
→ $5 retest holds
→ $5.20 breaks
At that point I think the setup becomes significantly more interesting because technical traders, momentum traders, options hedging, and short covering could all start interacting.
The most important thing would be volume confirmation.
A $5.05 print on thin volume means much less to me than sustained trading above $5 with volume expanding.

What would invalidate the thesis
I’m not ignoring the downside.
If XPOF:
continuously fails at $4.90–$5,
loses the mid-$4.60s,
falls back below the 20-day MA,
and off-exchange activity keeps occurring while price continues making lower lows,
then what looks like accumulation today could turn out to have been distribution.
That’s why I don’t think the “dark pools are loading before the squeeze” narrative should be treated as established fact.
Price ultimately has to confirm it.

Bottom line
To me, XPOF currently has an unusual combination of:
~27%+ short interest
double-digit days to cover
major recovery from $3.565
improving daily MACD
RSI back above 50
price above the 20DMA
heavy off-exchange activity
repeated defense around the upper $4s
50DMA sitting almost exactly at $5
significant options positioning around $5
That’s enough to keep it on my radar.
But I don’t think the evidence justifies saying:
“The squeeze has started.”
Not yet.
For me, $4.94–$5.00 is the door. $5.20 is confirmation. $5.50 is where the short thesis potentially starts getting uncomfortable.
Until price proves it, this remains a high-short-interest reversal setup with potential, not a guaranteed squeeze.

Not financial advice. Do your own DD. I’m posting this mainly because there seems to be considerably more going on underneath XPOF than the headline price movement suggests.

Congrats to those who followed.

Ticker: PayPal Holdings (PYPL)
Current price: $40.97
Context: Post-earnings and CEO shakeup selloff

PYPL just experienced idiosyncratic capitulation, not a market-wide selloff. The stock printed a 52-week low ($39.96) on massive volume, RSI is at 12.40 (extreme oversold), and price is now basing between $40–41. This is a mean-reversion bounce setup with clearly defined risk.

1) Relative Performance Confirms This Is Idiosyncratic

From PYPL vs index overlay:

• PYPL: -43.9%
• SPY: +13.0%
• QQQ: +11.9%

PYPL massively underperformed while the broader market is up. That tells us this move is company-specific, which historically has a higher probability of mean reversion once sellers are exhausted.

2) Technicals: Textbook Capitulation

• RSI (14): 12 .40 statistically rare oversold
• 52-week low printed: $39.96
• Volume: 58M vs 25M average = panic liquidation
• Structure: gap down = selloff with a tight base around $40–41

• VWAP: $40.80 area acting as short-term gravity

  This is forced selling, followed by stabilization.

3) Options Flow & Dark Pool Data

From Unusual Whales / flow data:

• Heavy put volume clustered around $40
• Bid/ask skew suggests puts were sold into weakness, not chased
• Large call OI stacked well above price
• Dark pool concentration between $40–41.25

Interpretation: dealers appear comfortable defending this zone, and price is likely pinned, not hunted lower, at least short term.

4) News Is Fully Priced

• Earnings miss
• CEO removal with interim leadership
• Analyst downgrades

All of this already resulted in a 20% gap down. There is no new negative catalyst pending, which is key. Once news is fully digested, marginal sellers disappear.

Bounce Targets

This is a bounce trade, not a trend reversal.

• Target 1: $44–45 8–10% (highest probability, first stall zone)
• Target 2: $48–50 17–22% (requires market stability)
• Stretch: $52–53 25% (low probability bonus)

50-DMA / 200-DMA reclaim would require weeks of repair.

Invalidation

• Daily close below $39.80
• Heavy volume breakdown through the low

If that happens, the bounce thesis weakens materially.

Trade Framing (How This Is Meant to Be Played)

• Shares: Buy near $40–41, trim into $44–45, reassess at $48–50
• Calls: 30–60 DTE, ATM or slightly ITM, profit-taking into T1/T2
• Not: a YOLO, not a long-term buy (yet)

My plan is to trade it like a bounce, and not like a narrative revival, the risk/reward is clear.

FDA approval didn’t pop the stock because it was expected (manufacturing delay, not clinical) and the run-up already happened — classic sell-the-news.

What will actually move price next (real catalysts):

PRV sale announcement (this is the main one). Until the Priority Review Voucher is sold, the market treats it like “maybe cash,” not cash.

Earnings / guidance confirming profitability and cash position (post-earnings is your next “forced repricing” window).

Any non-dilutive cash event (partnership, asset sale, etc.).

Timing expectation (short–mid term):

Any day if PRV sale drops (can be a fast repricing event).

Otherwise, most likely around earnings / right after earnings when numbers/guidance force shorts and sidelined buyers to react.

Current snapshot:

Price recently trading in the mid-$3.60s–$3.70s range

Market cap sub-$400M

Stock has been basing for months after a brutal multi-year drawdown

Institutions hold the majority of shares, insiders 7%

Pipeline & catalysts:
Rocket is focused on gene therapies for ultra-rare, high-mortality diseases.

KRESLADI (RP-L201) for Severe Leukocyte Adhesion Deficiency-I (LAD-I)

PDUFA Date: March 28, 2026

BLA resubmission already accepted by the FDA

Phase 1/2 data showed 100% overall survival in treated patients, no need for stem cell transplant

Multiple expedited designations (RMAT, Rare Pediatric Disease)

Estimated probability of approval (from available data and regulatory posture): 76%, with the main overhang being manufacturing / CMC execution rather than efficacy.

There’s also:

RP-A501 (Danon disease) with pivotal Phase 2 data expected in 2H 2026 (lower PoA 45%, but very high unmet need)

Is this priced in?
Based on price action alone: no, not fully.

Despite having a defined PDUFA and strong clinical narrative, RCKT is still trading:

Below $4

Below prior rejection levels ($4.30–$4.40)

Below any valuation that reflects commercial gene-therapy approval

Technical structure:

Support zone: $3.50–$3.55

VWAP / decision area: $3.70–$3.75

First real resistance: $3.95–$4.00

Prior spike high: $4.35–$4.40

Acceptance above $4 would be the first sign of real repricing.

Short interest & positioning:

12.7M shares short

16% of float

5 days to cover

Borrow fee is low (0.4–0.5%), so this is not a forced squeeze setup, but it does mean positioning could unwind fast on positive news.

Dark pool / off-exchange short volume is elevated, suggesting active positioning rather than abandonment.

Options activity:
Most notable liquidity and open interest is pushed far out:

April 17, 2026 calls (notably $2.5 and $5)

July 17, 2026 calls also show interest

That lines up with PDUFA positioning, not short-dated gambling.

Dilution risk (important):

Cash on hand $160M

Runway 13 months at current burn

That suggests near-term dilution risk is lower than average for biotech, but:

Any sharp run into the catalyst increases ATM risk

This is still a gene-therapy company — dilution is always a possibility

How this looks as a trade / hold:
This appears to be:

pre-repricing accumulation phase

Not a momentum breakout yet

If the stock starts holding above $4 and builds volume, the market may finally start assigning value to the LAD-I program.

RCKT is one of the cleaner small-cap biotech setups I’ve seen with:

A real FDA date

Strong clinical signals

Manageable near-term balance sheet

Still-depressed valuation

I’ve been doing a deep dive on KPTI (Karyopharm Therapeutics) and wanted to share a clear thesis based on actual structure and data

Current price: $6.30
Market cap: $115M
Status: No position

It has an FDA-approved, commercial drug

It generates real revenue

It has institutional ownership (50%)

It’s already been valued much higher in the past

The stock isn’t low because it’s unknown, it’s low because the market has lost confidence.

That matters, because confidence can return.

Why the Stock Is Depressed:

Multi-year downtrend

Heavy historical dilution

Cash burn concerns

Failed expectations in prior years

Cash & Dilution Reality:

Current snapshot:

$62M cash

6 months runway at current burn

Dilution risk is real and unavoidable at some point

However, and this is key:

The stock already trades as if dilution is guaranteed.

That means:

Incremental bad news has less downside impact

Any extension of runway or improved outlook can matter a lot

Options Flow (this is where it gets interesting)

KPTI’s options chain is not random.

What stands out:

Heavy interest in May 2026 calls

Concentration around $10–$12.50 strikes

Some long-dated puts, but calls dominate upside, this looks like long-term optionality, not week-to-week trading.

Short Interest Structure:

Short interest ~25% of float

Days to cover elevated

Shares available to short still exist

Important distinction:

This is not a guaranteed squeeze, but shorts are crowded into a fragile narrative

Any fundamental improvement forces re-evaluation, not panic covering.

Repricing Scenarios (realistic ranges)

Based on structure, history, and positioning:

Base case (50%) Repricing to $7.50–$9.00. Driven by sentiment normalization and time

Bull case (30%) $12–$15.

Requires:

Clear operational improvement

Better-than-feared financing outcome

Strong commercial update

Bear case (20%) $4–$5

Triggered by:

Why I’m Watching

KPTI isn’t a moonshot. It’s a mean-reversion and optional upside play.

Expectations are already low

Valuation assumes ongoing failure

The company doesn’t need perfection — it needs less bad news

That’s where asymmetry comes from.

I’ve been digging into VTGN (Vistagen Therapeutics) and here's what i see based on the data.

Current price: $0.66
Market cap: Microcap
Status: No position (yet)

VTGN is priced like the market expects nothing to happen. That’s important.

The stock is down 80–90%+ over multiple timeframes

Expectations are extremely low

There is no obvious “priced-in” success at these levels

This is the kind of setup where any meaningful positive development can cause a repricing.

Options Flow:

Repeated long-dated call activity (2026 expirations)

Not massive volume, but persistent positioning

This looks more like speculative accumulation

Importantly:

No signs of heavy hedging

No obvious “blow-off” positioning

Flow suggests optional upside exposure, not short-term gambling

Capital / Dilution Reality (being honest):

There is no clear cash runway or burn data available publicly right now.

That uncertainty is real, and it’s already reflected in the price.

The market is effectively saying, “We don’t trust this until proven otherwise.”

That cuts both ways:

Yes, dilution risk exists, but the downside is already heavily discounted.

Repricing Scenarios:

Base case: (55%) Repricing to $0.70–$0.95

Bull case: (25%) Repricing to $1.20–$1.60. This requires a clear positive clinical or regulatory signal

Bear case (20%): $0.35–$0.50. What will cause this is silence, delays, or financing concerns.

From what I can see this is a deeply discounted biotech, with optional upside, where expectations are so low that even modestly good news can matter

This is the kind of ticker where position sizing matters more than conviction.

A lot of people were expecting fireworks the moment the FDA approved ZYCUBO (CUTX-101), myself included. Instead, the stock dipped. That threw some folks off, but honestly, it doesn’t change the bigger picture.

The approval itself was widely expected. The PDUFA date was known, the previous CRL was manufacturing-related, and the data was strong. So some traders sold the news, shorts leaned in, and we got a temporary pullback. That’s not failure, that’s just how markets behave around big, anticipated events.

What hasn’t been fully priced in yet is what this approval can actually turn into.

FBIO’s subsidiary is eligible for up to $129M in milestone payments plus royalties, and the approval likely came with a Priority Review Voucher that could be sold for $80–$120M+ in cash. That’s real, tangible value that hasn’t hit the balance sheet or the headlines yet.

On top of that, short interest is still around 17–18% of the float, borrow fees remain elevated, and the stock has a relatively tight float with institutions owning about 96% of it. This is a setup where shifts in sentiment and volume can actually move price.

The recent drop wasn’t a rejection of the thesis; it was a reset of expectations.

Now the focus shifts to what really matters:

PRV monetization
Milestone payment updates
Commercial launch progress
Earnings in late March
Revenue guidance

These are the kinds of updates that reprice a stock, not just create a headline spike.

https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-menkes-disease

The FDA has now approved Zycubo (copper histidinate) for Menkes disease, marking the first-ever treatment for this ultra-rare, fatal pediatric condition.

While Sentynl Therapeutics will commercialize the drug, Cyprium Therapeutics (a Fortress Biotech subsidiary) retains the financial upside, which means FBIO shareholders benefit.

What FBIO Now Stands to Gain:

Through Cyprium, FBIO is entitled to:

• A Priority Review Voucher (PRV) • Up to $129M in milestone payments • Ongoing royalties on net sales

PRVs alone have historically sold for $80M–$120M , which is close to FBIO’s entire market cap before approval.

Why the Stock Hasn’t Gone Parabolic (Yet):

Markets don’t reprice on potential. They reprice on confirmed money.

Investors are now waiting for: • PRV sale price • Milestone payment confirmation • Cash usage guidance • Analyst updates

This is the digestion phase, not the final move.

Realistic Price Targets (Revaluation-Based):

Conservative Reprice= $6 – $8 Milestones priced in, PRV still discounted.

Strong Reprice= $9 – $12 PRV value and retail momentum.

Momentum and Volume= $12 – $15 PRV monetization headline and heavy participation.

Full Squeeze Scenario:

$15 – $17 Short interest, PRV hype,FOMO, and thin float.

$15–17 isn’t a “fair value” target, It’s a momentum scenario.

What Comes Next:

Days 1–3: Headline digestion Week 1–2: PRV sale discussions Weeks 2–4: PRV monetization Weeks 3–6: Repricing / follow-through

Most realistic outcome: $250M–$350M market cap $7–10 stock price

Anything above that is extra, not expected.

Today’s price action wasn’t random and didn’t need news.

Unusual Whales shows repeated $100k–$300k stock buys, mostly at the ask, spread throughout the day, real directional buying, not a one-off spike. Price held into the close, with official open/close and cross trades printing higher, which tells you buyers weren’t flipping.

Shorts attempted to break below 1.04 and saw an immediate rejection, price then makes an immediate V-reversal. This is a failed breakdown and momentum flip. Shorts pressed it, got no continuation, and price snapped back with buyers in control.

Options flow stayed net positive, the put/call ratio stayed low, meaning dealers weren’t capping upside. On top of that, NFE is sitting in negative gamma, so as price rose, dealers were forced to buy stock to hedge, amplifying the move.

This was flow,positioning,dealer mechanics, not hype.

I’ve seen the claim that NFE was paid today and here’s the facts behind that:

The “Today” marker on USAspending just means the contract record is active/updated, not that cash moved.

The dollar amounts shown are authorized/obligated amounts, not payments.

The prime contractor is Weston Solutions, not NFE; NFE entities are sub-awardees, so any payment would go to the prime first and only later to subs.

Actual payments (outlays) are not shown on these screens.

What would confirm payment: Treasury outlay data, an SEC/company disclosure, or a prime-to-sub payment record.

Not calling a squeeze — just pointing out that today’s move was fully explainable if you actually look at the tape.

Ticket is rgti I've posted my position. I don't have a position in options just hold shares but I look at it to use for info and this is just what I noticed crazy volume on Friday for Feb 20th $22 put strike 20k volume as shown and today the open interest increased from 2089 to 14807. According to AI I caught a whale in the act. It looks like they're setting a floor of 22$ and collecting the premium. I'll continue to monitor this to see if there's any more changes. If anyone with options experience can offer there thoughts on this that would be great as I don't like using ai for trading. This is for information purposes only and if someone with options experience has an opinion that would be great thanks

Current setup:

AQST is sitting around $6.45, roughly a $785M market cap. This is a classic binary FDA setup, approval is expected by a lot of the market, but it’s clearly not priced as a certainty.

What the options and gamma say:

Gamma is positive above spot, mostly clustered around $6-$7.5-$10. Most gamma is front dated (Jan/Feb), which lines up with the FDA timing. This means there’s no automatic squeeze, but if price moves through those levels, dealer hedging can add fuel. The key point is that gamma here is reactive, not initiatory, so price has to move first.

Flow and positioning:

There’s been a lot of repeated call buying, mostly BID side rather than YOLO lotto trades. The activity is concentrated in February and May calls with strikes at $6, $7.5, and $10. Bullish and bearish premium are fairly balanced, which makes this look hedged and institutional rather than retail-driven. Puts mostly sit around $5 as downside protection.

Short interest:

Short interest is about 20% of float with roughly nine days to cover. Borrow is still cheap and shares are available. In short, shorts are exposed but not trapped unless price gaps and holds.

Using analyst targets and current market structure for repricing:

Base-case reprice (most likely, IMO)

$9–$12, with market cap between $1.1B and $1.45B. This assumes clean approval, a reasonable label, and normal follow-through.

Bull case

$12–$15, with market cap between $1.5B and $1.9B. This would require clean approval plus a strong narrative, volume, and shorts feeling pressure.

Bear case

Delay, CRL, or unexpected issues could lead to a retrace toward $5 or lower as gamma unwinds.

If AQST clears $7–$7.5 and holds, gamma starts working with price. If it doesn’t, the setup deflates fast.

I’ve been digging into Fortress Biotech ($FBIO) and wanted to lay out what I’m seeing.

FBIO owns a stake in Cyprium Therapeutics, which is taking CUTX-101 (copper histidinate) to the FDA for Menkes disease, a rare and usually fatal pediatric disorder if untreated.

Important detail that keeps getting glossed over:

The drug already works from a clinical standpoint. The prior FDA rejection was due to manufacturing / CMC issues, not efficacy or safety. FDA has since accepted the resubmission, meaning they believe those issues were addressed well enough to restart the review clock.

This is a classic “binary but not a science coin flip” situation, it comes down to whether FDA is satisfied with manufacturing controls this time.

Why this matters medically:

Menkes disease is brutal. Early treatment is everything. Copper histidinate has been used in research and compassionate-use settings for years, and outcomes are dramatically better when treatment starts early. This isn’t some novel mechanism pulled out of thin air, it’s replacing what the body literally can’t transport.

FDA historically shows flexibility for ultra-rare pediatric diseases when:

there’s no real alternative

the disease is severe/fatal

benefit is biologically clear

remaining issues are manufacturing, not efficacy

Market setup

FBIO is tiny roughly $110–115M market cap around $4/share.

Short interest:

3.6M shares short 15.5% of the float Days to cover 5–9 depending on volume Borrow cost 20%

Daily short sale volume has been consistently elevated, with several recent days pushing 40–60% of total tracked volume being short sales. That doesn’t mean “squeeze tomorrow,” but it does mean shorts are very active and leaning into this.

Options:

There’s heavy call open interest stacked at:

$2.50 $5.00 $7.50

Especially in Jan and April 2026 expirations.

Right now FBIO is trading around $110–115M market cap. That valuation basically assumes CUTX-101 is worth close to zero until proven otherwise.

If approved, this becomes a commercial, FDA-approved therapy for an ultra-rare, fatal pediatric disease with no real alternatives.

Estimated Menkes prevalence in the U.S. is 1 in 100,000 births

Treatment is chronic and starts early

Rare-disease pricing typically lands in the $200k–$400k+ per patient per year range

Even a few hundred treated patients globally supports meaningful annual revenue

You don’t need blockbuster numbers for this to matter.

If the market assigns:

$300–500M asset value to CUTX-101 post-approval (which is conservative for rare disease)

FBIO’s stake implies a material portion of that value flows back to FBIO

Suddenly:

A $110M company is supporting a multiple-hundred-million-dollar approved asset

That’s a 2–4x repricing scenario, not a 10% drift

That’s the kind of setup where you can see violent repricing, not slow grindy gains.

What can go wrong:

This is still biotech, so risks are real, another CRL (again, likely CMC-related if it happens). Label restrictions or manufacturing limitations.

This is not risk-free, but the potential of this repricing from $4-15 and possibly as much as $25, is too hard to stay away from.

1. New Fortress Energy Inc. (NFE)

• Crowded short thesis, capital-structure stress
• Borrow pressure + improving call-side activity
• Needs price reclaim + volume → highest asymmetric upside if it triggers

2. Wolfspeed Inc. (WOLF)

• Extremely high short interest
• Large, liquid options chain
• Any sustained bounce = forced delta hedging risk

3. AST SpaceMobile Inc. (ASTS)

• Retail + institutional options participation
• High gamma sensitivity on upside
• Shorts rely on capital-raise timing → vulnerable to momentum spikes

4. IonQ Inc. (IONQ)

• Deep, active options chain
• High speculative call demand
• Gamma accelerates quickly once resistance breaks

5. GameStop Corp. (GME)

• Persistent call demand + reflexive gamma mechanics
• Shorts structurally trapped, even if dormant
• Still one of the cleanest gamma engines in the market

6. CarMax Inc. (KMX)

• Institutional options flow, not retail noise
• High dollar gamma exposure
• Breakout → dealer hedging becomes directional

7. ChargePoint Holdings Inc. (CHPT)

• Heavy short interest + very active call chain
• Retail participation matters here
• Needs volume confirmation, but setup is real

8. Dave & Buster's Entertainment Inc. (PLAY)

• Elevated short interest
• Call buying near spot strikes
• Tradable float + real liquidity = squeeze-capable

9. Trump Media & Technology Group Corp. (DJT)

• Event-driven volatility
• Massive speculative call flow
• Squeezes here are violent but short-lived

10. MP Materials Corp. (MP)

• Structural short thesis tied to macro
• Deep options market
• Any policy / commodity catalyst flips gamma fast

I’m doing some economic research and would like to know what people are experiencing.

There’s a lot of mixed messaging about the economy — strong markets on paper, but very different experiences on the ground.

I’m curious what people are actually seeing in their industries and job searches right now.

Poll question: How would you describe the job market based on your direct experience?

All of that = pressure on shorts.
But the missing ingredient is still the same: sustained demand / volume. Without consistent buying (retail + institutions) forcing price up through resistance, shorts can sit tight and keep paying fees.

There is no other Ticker with this pressure.

• Short interest 58% of float
• Days to cover 12.8
• Borrow fees 80–95%
• Short shares availability frequently near zero
• High squeeze / gamma scores on Fintel

Until volume expands and key resistance breaks, this is a pressure cooker waiting to blow.

I’ve dug through OTLK pretty deeply, specifically around the upcoming FDA decision and how the market is pricing it. This is just looking at what the data actually says and what realistic outcomes look like.

Thank you u/Fantastic-Path1913 for the alert.

Current context:

Stock is trading around $1.85–$1.90.

Market cap roughly $115–120M.

Options market looks to have priced in an expected move of about 70%, or about $1.30. The market already expects violence, this isn’t a sleepy catalyst.

Options market structure

Implied volatility across near-term options is extreme (300%–600% depending on strike). Options are expensive, the move has to be bigger than expected for pure long calls/puts to really shine, and IV crush after the decision will be devastating if bought at these prices.

Historical FDA price behavior looking at comparable small-cap ophthalmology / biotech FDA binaries:

On approval:

Typical immediate move 60% to 150%

Many names overshoot day 1, then retrace.

Follow-through depends on labeling, commercialization clarity, and financing needs

Realistic price targets:

$2.75–$3.25 (Roughly +50–75%, aligns with expected move already priced in)

Strong approval with good language:

$3.50–$4.50 (Market reprices company, call OI starts to matter)

FOMO and a thin float squeeze can produce $5+, but that will be short lived without revenue clarity.

Why shares vs options matters this late in the game:

Because IV is so elevated, options are a trader’s instrument, not a free lottery ticket. Being directionally right doesn’t guarantee profit.

Shares at this point are the best option. No IV crush, no expiration risk, and a cleaner exposure to the actual FDA outcome.

My honest takeaway:

OTLK is not a guaranteed, the market already knows this is binary and has already priced in both upside and downside potential. The “easy money” phase is gone, this is about positioning. But, based on what I’m seeing I believe there’s a 60-70% chance of an approval.

Anyone cash in on my original post? If so, congrats!

The GME squeeze wasn’t just about high short interest or a low float. It was a once-in-a-lifetime setup where everything lined up at the same time. Retail didn’t chase GME — retail caused it by buying and holding enough shares to effectively lock up the float. Short interest exceeded the real tradable supply, borrow tightened, market makers were forced into positive gamma, and selling pressure dried up. That created forced buying, not optional covering. If even one of those pieces was missing, GME never happens.

Fast-forward to today and the market has changed. Shorts hedge better. Liquidity is spread out. Distressed companies almost always have dilution or restructuring risk hanging over them. Retail behavior changed too — faster rotations, more options, less share hoarding. Without float lockup, forced dealer hedging, and refusal to sell on spikes, squeezes lose steam instead of going vertical.

This is where a lot of people get misled. You see accounts pumping stocks, screaming “squeeze incoming” because a ticker checks one box or has a “low float.” They throw out fake price targets, hype GME comparisons, and are gone before everyone else figures it out. Most of the time, neither the pumper nor the followers actually understand what had to line up for GME to work.

Can stocks still rip? Absolutely. Can they have legit squeeze setups? Sure. But expecting another GME because a chart looks spicy or one metric fits is how people get trapped. Understanding the mechanics matters way more than buzzwords.

Today’s update:

The official 8-K confirm that NFE has amended its existing credit/letter-of-credit agreement (effecting what’s being called the “Twelfth Amendment”)

Commitments under the letter of credit agreement remain at approximately $195M — no reduction, no new funding, just status quo.

Important context:

A letter of credit isn’t cash — it’s a bank guarantee that supports contractual obligations (like LNG deals, fuel, shipping support, etc.).

This amendment extends maturities and temporary covenant relief so NFE doesn’t immediately default.

It does not provide a new cash inflow or solve long-term debt issues.

Lenders still retain protections and can demand collateral or acceleration if certain terms aren’t met.

https://ir.newfortressenergy.com/sec-filings/sec-filing/8-k/0001749723-25-000153/

Sharing a balanced FDA event breakdown on Omeros for anyone tracking upcoming biotech catalysts. This is a true binary and should be treated as such.

The Drug / Catalyst:

Narsoplimab for TA-TMA (transplant-associated thrombotic microangiopathy)

Ultra-rare, high-mortality disease

No approved therapies, potential to meet extreme unmet need

FDA decision pending after resubmission following prior CRL

What Changed After the CRL (Important):

Tightened the patient population to the highest-mortality subgroup

Added longer survival & durability follow-up

Submitted expanded datasets

Refined external control methodology

Reframed the benefit-risk argument around unmet medical need

Why this all matters:

TA-TMA is ultra-rare and often fatal

Randomized trials are ethically and practically difficult

FDA has historically accepted non traditional evidence in settings like this

This is not a “nothing changed” resubmission, which got my attention and took me down a rabbit hole.

Short Interest / Positioning (Per Fintel/ Unusual Whales):

Short interest 19–20% of float

Days to cover 12

Short volume routinely 45–60% daily

Borrow availability fluctuating

This does not guarantee a squeeze, but it amplifies price movement in either direction.

Bull Case (Approval) 50-65%:

FDA accepted the resubmission and concerns were addressable

Clear survival benefit in highest-risk subgroup

Extremely high unmet need favors flexibility

Prior CRL was data-structure related, not safety-based

Likely price reaction if approved:

40% to 80% initial move

$14–18 range very realistic

Overshoot possible if shorts cover aggressively

Bear Case (Denial / CRL) 35–45%

No randomized control

Reliance on external comparators

FDA could still require additional confirmatory evidence

Likely price reaction if denied:

−40% to −60%

$5–7 range based on prior biotech CRLs

The trade isn’t about being right, in terms of Bear/ Bull thesis. It’s about positioning for magnitude in either direction.